openPR Logo
Press release

Glaucoma - Pipeline Insight, 2025: Advancing Beyond IOP Control Toward Neuroprotection and Vision Preservation | DelveInsight

07-04-2025 03:46 PM CET | Health & Medicine

Press release from: DelveInsight

Glaucoma Pipeline

Glaucoma Pipeline

Glaucoma, a leading cause of irreversible blindness worldwide, is traditionally managed through therapies that lower intraocular pressure (IOP). However, as understanding of the disease evolves, there is growing recognition of the need for neuroprotective strategies that address underlying optic nerve damage and retinal ganglion cell (RGC) loss.

DelveInsight's "Glaucoma - Pipeline Insight, 2025" analyzes over 50+ emerging therapies that go beyond conventional IOP-lowering agents. The pipeline includes novel mechanisms such as ROCK inhibitors, nitric oxide-donating agents, neuroprotective peptides, complement pathway inhibitors, and gene therapies aimed at preserving vision and halting disease progression.

Key companies driving innovation include Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, and TearClear, with many candidates in late-stage development or in combination regimens to enhance efficacy. Several therapies target underserved segments, such as normal-tension glaucoma or treatment-resistant patients.

The report offers detailed insights into trial designs, delivery systems (e.g., sustained-release implants, nanocarriers), and biomarkers for early diagnosis and response monitoring. As glaucoma care shifts toward holistic disease management, emerging therapies are aiming not just to reduce IOP but to preserve long-term visual function and quality of life.

This evolving landscape reflects a shift toward comprehensive, disease-modifying approaches that could transform glaucoma care in the coming years

Interested in learning more about the current treatment landscape and the key drivers shaping the Glaucoma pipeline? Click here: https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Glaucoma Pipeline Report
• DelveInsight's glaucoma pipeline analysis depicts a strong space with 50+ active players working to develop 50+ pipeline drugs for glaucoma treatment.
• The leading glaucoma companies include Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others are evaluating their lead assets to improve the glaucoma treatment landscape.
• Key glaucoma pipeline therapies in various stages of development include DE-130A, PDP-716, NCX 470, DE-126, PHP-201, Citicoline, TRS01, TC-002, T4032, Bremen, POLAT 001, BTQ-1902, Nyxol, IN-A010, VVN539, and others.
• In May 2025, OcuSciences received FDA clearance for its OcuMet Beacon, a proprietary non-invasive device for assessing retinal health.
• In April 2025, BVI Medical received FDA 510(k) clearance for its Leos system, a minimally invasive glaucoma device offering Laser ECP with endoscopic visualization. Leos reduces IOP by targeting aqueous humor production and is backed by emerging clinical trial data.
• In December 2024, Gland Pharma received USFDA approval for its Latanoprost Ophthalmic Solution 0.005% (2.5 mL), a generic equivalent to Xalatan, for treating elevated intraocular pressure in open-angle glaucoma and ocular hypertension.

Request a sample and discover the recent breakthroughs happening in the glaucoma pipeline landscape at https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Glaucoma Overview
Glaucoma is a chronic, progressive eye disease that damages the optic nerve and is one of the leading causes of irreversible blindness worldwide. It is most commonly associated with elevated intraocular pressure (IOP), which results from impaired drainage of aqueous humor from the eye. However, glaucoma can also develop in individuals with normal IOP, highlighting the complexity of its underlying pathophysiology. The disease is typically asymptomatic in its early stages, earning it the nickname "the silent thief of sight," as significant vision loss can occur before a patient becomes aware of any issues.

There are several types of glaucoma, with the most common being primary open-angle glaucoma (POAG) and angle-closure glaucoma. Other less common types include normal-tension glaucoma, congenital glaucoma, and secondary glaucomas resulting from other medical conditions or trauma. Risk factors include age, family history, race (especially African or Asian descent), diabetes, and long-term corticosteroid use.

Current treatment strategies primarily aim to reduce IOP through medications (such as prostaglandin analogs, beta-blockers, and carbonic anhydrase inhibitors), laser therapy, or surgery. However, these interventions do not address the underlying neurodegeneration, and many patients continue to experience progressive vision loss despite controlled IOP. As a result, there is a growing focus on developing neuroprotective and regenerative therapies to prevent optic nerve damage and preserve vision.

Find out more about glaucoma medication at https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Glaucoma Treatment Analysis: Drug Profile
NCX 470: Nicox Ophthalmics GmbH
NCX 470 is a next-generation nitric oxide (NO)-donating prostaglandin analog being developed by Nicox Ophthalmics. It combines the intraocular pressure (IOP)-lowering effects of prostaglandin F2α activity with the additional benefits of nitric oxide, which may improve ocular perfusion. This dual mechanism could make NCX 470 one of the most effective single-agent treatments for lowering IOP in patients with open-angle glaucoma or ocular hypertension. The drug is currently in Phase III clinical development.

DE-126 (ONO-9054): Santen Pharmaceuticals
DE-126 is a novel, once-daily prostaglandin analog eye drop designed to reduce IOP through a dual mechanism-activation of both FP and EP3 prostaglandin receptors. Since both receptors play a role in IOP reduction, DE-126 is expected to deliver superior efficacy compared to conventional FP receptor agonists. It is currently in Phase III clinical trials for open-angle glaucoma and ocular hypertension.

POLAT-001: Peregrine Ophthalmic
POLAT-001 is an extended-release formulation of latanoprost, delivered through nanoliposomes approximately 100 nm in size. This innovative liposomal platform, known as Lipolat, represents a significant advancement in ophthalmic nanomedicine, offering sustained drug delivery for glaucoma treatment. POLAT-001 has completed a pilot Phase IIa trial in the U.S. for the treatment of glaucoma.

Learn more about the novel and emerging glaucoma pipeline therapies at https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Glaucoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Scope of the Glaucoma Pipeline Report
• Coverage: Global
• Key Glaucoma Companies: Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others.
• Key Glaucoma Pipeline Therapies: DE-130A, PDP-716, NCX 470, DE-126, PHP-201, Citicoline, TRS01, TC-002, T4032, Bremen, POLAT 001, BTQ-1902, Nyxol, IN-A010, VVN539, and others.

To dive deep into rich insights for drugs used for glaucoma treatment, visit: https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Glaucoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Glaucoma Pipeline Therapeutics
6. Glaucoma Pipeline: Late-Stage Products (Phase III)
7. Glaucoma Pipeline: Mid-Stage Products (Phase II)
8. Glaucoma Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Glaucoma - Pipeline Insight, 2025: Advancing Beyond IOP Control Toward Neuroprotection and Vision Preservation | DelveInsight here

News-ID: 4093011 • Views:

More Releases from DelveInsight

Fuchs Dystrophy Pipeline Insight 2025: Emerging Cell and Gene Therapies Reshape the Future of Corneal Disease Treatment | DelveInsight
Fuchs Dystrophy Pipeline Insight 2025: Emerging Cell and Gene Therapies Reshape …
DelveInsight's "Fuchs Dystrophy - Pipeline Insight, 2025" explores the dynamic pipeline for Fuchs Endothelial Corneal Dystrophy (FECD), a progressive eye disease characterized by corneal endothelial cell loss, leading to vision impairment and potential blindness. Current treatment relies on corneal transplantation, which is limited by donor shortages and surgical risks. The pipeline showcases novel cell-based therapies, including endothelial cell injection and regenerative strategies designed to restore corneal transparency without the need for
Polycystic 0vary Syndrome (PCOS) Pipeline Insight 2025: Innovative Hormonal and Metabolic Modulators Redefine Care Pathways | DelveInsight
Polycystic 0vary Syndrome (PCOS) Pipeline Insight 2025: Innovative Hormonal and …
DelveInsight's "Polycystic 0vary Syndrome - Pipeline Insight, 2025" provides a thorough analysis of emerging therapeutic strategies for PCOS, a common endocrine disorder affecting reproductive-age women and associated with infertility, metabolic dysfunction, and psychological comorbidities. Current management relies heavily on lifestyle modification and symptom-targeted pharmacotherapy, leaving substantial unmet needs. The pipeline features novel hormonal modulators, including selective androgen receptor antagonists, estrogen receptor modulators, and progesterone analogs, designed to restore hormonal balance
Influenza A Virus H5N1 Subtype Pipeline Insight 2025: Next-Generation Vaccines and Antivirals Target a Global Health Threat | DelveInsight
Influenza A Virus H5N1 Subtype Pipeline Insight 2025: Next-Generation Vaccines a …
DelveInsight's "Influenza A Virus H5N1 Subtype - Pipeline Insight, 2025" presents a detailed overview of the therapeutic landscape for H5N1, a highly pathogenic avian influenza virus associated with severe respiratory disease and high mortality rates in humans. The pandemic potential of H5N1 continues to drive intense global R&D efforts. The pipeline is rich with next-generation vaccines, including mRNA-based platforms, recombinant protein vaccines, and universal influenza vaccine candidates targeting conserved viral epitopes.
Spasmodic Torticollis Pipeline Insight 2025: Novel Neurotoxins and Neuromodulation Techniques Aim to Improve Patient Outcomes | DelveInsight
Spasmodic Torticollis Pipeline Insight 2025: Novel Neurotoxins and Neuromodulati …
DelveInsight's "Spasmodic Torticollis - Pipeline Insight, 2025" provides a comprehensive analysis of the evolving treatment landscape for Spasmodic Torticollis (cervical dystonia), a chronic neurological disorder characterized by involuntary neck muscle contractions and abnormal head postures. Current standard therapies, including botulinum toxin injections, offer relief but remain limited by their variable duration of effect and the development of resistance. The pipeline features next-generation botulinum toxin formulations, designed to extend therapeutic duration and

All 5 Releases


More Releases for Glaucoma

Glaucoma Surgery Devices Market Report 2024 - Glaucoma Surgery Devices Market Si …
"The Business Research Company recently released a comprehensive report on the Global Glaucoma Surgery Devices Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The glaucoma surgery devices
Global Glaucoma Market
According to a new market research report published by Global Market Estimates, the Global Glaucoma Market is projected to grow at a CAGR value of 5.0% from 2023 to 2028. Growing awareness for early diagnosis of glaucoma have gained prominence due to various educational campaigns and screening programs. Early detection allows for timely intervention, leading to better disease management and reducing the risk of vision loss, thus propelling the market growth.
Glaucoma Treatment Market - Safeguarding Sight: Innovating Glaucoma Treatment fo …
Newark, New Castle, USA: The "Glaucoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Glaucoma Treatment Market: https://www.growthplusreports.com/report/glaucoma-treatment-market/8926 This latest report researches the industry structure, sales, revenue,
Glaucoma Surgical Devices Market By Device Type (Glaucoma Drainage Devices, Impl …
Glaucoma Surgical Devices market report presents a global overview of market shares, size, statistics, trends, demand, revenue and growth opportunities by key players, regions and countries. This report offers a complete market overview during the past, present, and the forecast period till 2032 which helps to identify future opportunities, risk factors, growing areas. Report also highlight on recent developments, technological innovations, market affecting factors, demographics analysis, demand and supply chain
Micro-Invasive Glaucoma Implants Micro-Invasive Glaucoma Implants
Global Micro-Invasive Glaucoma Implants Market Definition: Micro-invasive glaucoma implants is performed for the treatment of the open- angle glaucoma and is done through an ab- interno approach. It is very safe and provides faster recovery as compared to the traditional methods. They usually lower the intraocular by increasing the flow or reducing the production of the aqueous humor. Increasing cases of the glaucoma worldwide is the major factor fueling the
Glaucoma Surgery Devices Market 2016: Glaucoma Systems, Glaucoma Laser Devices
Latest industry research report on Glaucoma surgery devices are used in the glaucoma treating procedure. These procedures include both surgical and laser therapies performed on a patient. The cases of blindness due to glaucoma is on rise across the several countries. Furthermore, the demand for both technologically as well as advanced surgical equipment has resulted in the popularity of glaucoma surgery devices industry, worldwide. Sudden increase in the aging population and